Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29015080 | 1.00 | RIPK1 (0.39) | RIPK1SLC6A4SLC6A2SLC6A3AOC3 | |
| SCHEMBL29767113 | 1.00 | RIPK1 (0.39) | RIPK1SLC6A4SLC6A2SLC6A3AOC3 | |
| SCHEMBL29015081 | 1.00 | RIPK1 (0.39) | RIPK1SLC6A4SLC6A2SLC6A3AOC3 | |
| SCHEMBL17093268 | 1.00 | RIPK1 (0.39) | RIPK1SLC6A4SLC6A2SLC6A3AOC3 | |
| SCHEMBL27094502 | 0.84 | RIPK1 (0.53) | RIPK1AOC3LMNAKDM4EALDH1A1 | |
| SCHEMBL1520904 | 0.84 | RIPK1 (0.53) | RIPK1AOC3LMNAKDM4EALDH1A1 | |
| SCHEMBL15539656 | 0.81 | TRPA1 (0.38) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL15540392 | 0.81 | TRPA1 (0.38) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17093311 | 0.80 | ADRB2 (0.43) | AOC3HIF1A | |
| SCHEMBL28369160 | 0.80 | ADRB2 (0.43) | AOC3HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-116234798-A | Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders | 生物药品解决方案有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| CN-106507667-B | Sulfamate derivatives for the prevention or treatment of epilepsy | 比皮艾思药物研发有限公司 | 2020-01-24 | — | — | CN | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-03 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | SULT2A1, STS, SULT1A1 | RIPK1 2575/4885SLC6A4 19/4885SLC6A2 63/4885 |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | RIPK1 2828/4885SLC6A4 1/4885SLC6A2 3/4885 |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | MYLK, MUSK, MYLK2 | RIPK1 2631/4885SLC6A4 363/4885SLC6A2 462/4885 |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | STS, SULT2A1, GRIK5 | RIPK1 1224/4885SLC6A4 110/4885SLC6A2 271/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | RIPK1 2828/4885SLC6A4 1/4885SLC6A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.